Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral Research Award: Priority Announcement - Refugee Training Awards

University of Toronto

$105,000.00

Dual Targeting of Combination Therapy to Breast Cancer: A New Strategy to Overcome Drug Resistance

FY 2016-17

Summary
Human epidermal growth factor receptor-2 positive (HER2+) breast cancer (BC) is an aggressive subtype of BC associated with high recurrence rates and poor survival. The combination of the chemotherapeutic agent paclitaxel (PTX) and HER2 antibody targeted agent trastuzumab (TmAb) has been the gold first line therapy in advanced HER2+ BC for nearly two decades. However, the majority of patients develop TmAb resistance within the first year of treatment. Additionally, the conventional PTX formulation currently used (Taxol®) has been associated with dose-limiting neurotoxicities and severe hypersensitivity reactions. The use of mamalian target of rapamycin (mTOR) inhibitors, such as everolimus (EVER), has been shown to overcome TmAb resistance and increase sensitivity to PTX. Importantly, administering this combination at the synergistic ratio could allow for reducing PTX dose, thus, improving the toxicity profile of the drug. Polymeric nanoparticles designed to deliver cancer therapies to BC tumors have been explored, successfully demonstrating the use of this delivery system to reduce systemic toxicity and improve the antitumor effects of anti-cancer drugs. Furthermore, recent studies suggest that TmAb resistance is associated with and enhanced by an increase in expression of the epidermal growth factor receptor 1 (EGFR). Therefore, the goal of this research is to develop a novel polymeric nanoparticle formulation, actively targeted to both HER2 and EGFR receptors, to specifically deliver a combination of the cytotoxic agent PTX and EVER at their synergistic ratio to TmAb resistant HER2+ BC models. We believe this novel formulation will make for a powerful therapeutic for treatment of advanced HER2+ BC including TmAb resistant tumors, reduce the toxicities of PTX, thus, improving survival rates and the quality of life of patients with advanced HER2+ BC.
Program
Doctoral Research Award: Priority Announcement - Refugee Training Awards
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
363682
Name
Houdaihed Loujin S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Dual Targeting of Combination Therapy to Breast Cancer: A New Strategy to Overcome Drug Resistance
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Priority Announcement - Refugee Training Awards
Keyworddelim
Chemotherapy; Combination Therapy; Everolimus; Her2+ Breast Cancer; Nanoparticles; Nanotechnology; Paclitaxel; Polymeric Micelles; Targeted Drug Delivery; Trastuzumab
Abstract
Human epidermal growth factor receptor-2 positive (HER2+) breast cancer (BC) is an aggressive subtype of BC associated with high recurrence rates and poor survival. The combination of the chemotherapeutic agent paclitaxel (PTX) and HER2 antibody targeted agent trastuzumab (TmAb) has been the gold first line therapy in advanced HER2+ BC for nearly two decades. However, the majority of patients develop TmAb resistance within the first year of treatment. Additionally, the conventional PTX formulation currently used (Taxol®) has been associated with dose-limiting neurotoxicities and severe hypersensitivity reactions. The use of mamalian target of rapamycin (mTOR) inhibitors, such as everolimus (EVER), has been shown to overcome TmAb resistance and increase sensitivity to PTX. Importantly, administering this combination at the synergistic ratio could allow for reducing PTX dose, thus, improving the toxicity profile of the drug. Polymeric nanoparticles designed to deliver cancer therapies to BC tumors have been explored, successfully demonstrating the use of this delivery system to reduce systemic toxicity and improve the antitumor effects of anti-cancer drugs. Furthermore, recent studies suggest that TmAb resistance is associated with and enhanced by an increase in expression of the epidermal growth factor receptor 1 (EGFR). Therefore, the goal of this research is to develop a novel polymeric nanoparticle formulation, actively targeted to both HER2 and EGFR receptors, to specifically deliver a combination of the cytotoxic agent PTX and EVER at their synergistic ratio to TmAb resistant HER2+ BC models. We believe this novel formulation will make for a powerful therapeutic for treatment of advanced HER2+ BC including TmAb resistant tumors, reduce the toxicities of PTX, thus, improving survival rates and the quality of life of patients with advanced HER2+ BC.
Competitiondate
201610
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Houdaihed, Loujin S
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~